Loading...
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
BACKGROUND: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Selection of novel drug therapies for patients with relapsed/refractory aggressive lymphoma re...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4181623/ https://ncbi.nlm.nih.gov/pubmed/25279222 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-7771-2-16 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|